NASDAQ:TTHI - Transition Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.5248 0.00 (0.00 %) (As of 10/19/2018 04:00 PM ET)Previous Close$1.5248Today's Range$1.5248 - $1.524852-Week Range$0.66 - $2.75VolumeN/AAverage Volume70,238 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileDiscussionChartEarnings HistoryFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Transition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah. Receive TTHI News and Ratings via Email Sign-up to receive the latest news and ratings for TTHI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A SymbolNASDAQ:TTHI CUSIPN/A Webwww.transitiontherapeutics.com Phone+1-416-2607770 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on Equity-58.00% Return on Assets-47.29% Miscellaneous EmployeesN/A Outstanding Shares38,880,000Market Cap$0.00 Transition Therapeutics (NASDAQ:TTHI) Frequently Asked Questions What is Transition Therapeutics' stock symbol? Transition Therapeutics trades on the NASDAQ under the ticker symbol "TTHI." How were Transition Therapeutics' earnings last quarter? Transition Therapeutics Inc (NASDAQ:TTHI) posted its quarterly earnings results on Tuesday, September, 15th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.08. View Transition Therapeutics' Earnings History. How do I buy shares of Transition Therapeutics? Shares of TTHI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Transition Therapeutics' stock price today? One share of TTHI stock can currently be purchased for approximately $1.5248. What is Transition Therapeutics' official website? The official website for Transition Therapeutics is http://www.transitiontherapeutics.com/. How can I contact Transition Therapeutics? Transition Therapeutics' mailing address is 101 College St Suite 220, TORONTO, ON M5G 1L7, Canada. The biopharmaceutical company can be reached via phone at +1-416-2607770. MarketBeat Community Rating for Transition Therapeutics (NASDAQ TTHI)Community Ranking: 1.9 out of 5 ()Outperform Votes: 92 (Vote Outperform)Underperform Votes: 155 (Vote Underperform)Total Votes: 247MarketBeat's community ratings are surveys of what our community members think about Transition Therapeutics and other stocks. Vote "Outperform" if you believe TTHI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTHI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/19/2018 by MarketBeat.com StaffFeatured Article: How Do You Calculate Return on Equity (ROE)?